Keywords: elan, retires, million, debt, co-developer, troubled, would-be
Elan retires $240.0 million of 2008 debt
Article | 13 June 2005
Elan, the co-developer of troubled would-be blockbuster multiple sclerosis drug Tysabri (natalizumab; Marketletters passim) has retired $211.8 million of its 2008 outstanding ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
